Method for preparing carbamazepine PLGA (poly lactic-co-glycolic acid) copolymer micro capsule

A carbamazepine polylactic acid, glycolic acid copolymer technology, applied in microcapsules, capsule delivery, pharmaceutical formulations, etc., can solve the problems of wide distribution, low product bioavailability, high inlet air temperature, and achieve dissolution and dissolution. The effect of speed increase

Active Publication Date: 2014-03-05
CHINA PHARM UNIV
View PDF3 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] There are many difficult problems in the preparation of drug microcapsules by traditional methods, such as the low encapsulation efficiency of the emulsification-solvent evaporation method, the slow and controlled release effect is not good, and a large amount of organic solvents and surfactants are used in the preparation process; the spray drying method is based on the boiling point of the solvent, The selected inlet air temperature is higher; the product particle size of the ball milling method is larger and the distribution is wider, etc.
These problems lead to the difficulty of separating and purifying the product, the preparation conditions are not suitable for heat-sensitive drugs and biologically active substances, and the low bioavailability of the product.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for preparing carbamazepine PLGA (poly lactic-co-glycolic acid) copolymer micro capsule
  • Method for preparing carbamazepine PLGA (poly lactic-co-glycolic acid) copolymer micro capsule

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] figure 1 It is an equipment diagram for implementing the method of the present invention. The device mainly includes a carbon dioxide delivery system and an autoclave. The main implementation process is: placing carbamazepine and polylactic acid-glycolic acid copolymer on the lower and middle sintering plates of the injection kettle respectively; Start the injection kettle heater, and after the temperature in the kettle reaches the preset value, the carbon dioxide in the steel cylinder flows through the low-temperature constant temperature tank to liquefy, is compressed by the high-pressure pump and preheated by the preheater, and then passes into the injection kettle from the bottom of the kettle; Raise the pressure in the kettle, and when the temperature and pressure are stable, maintain it for a certain period of time; close the carbon dioxide inlet valve, discharge the carbon dioxide in the kettle through the throttle valve, and release the pressure to normal pressur...

Embodiment 2

[0030] The supercritical fluid injection method of the present invention makes the carbamazepine polylactic acid-glycolic acid copolymer microcapsules with a drug loading of 28.1%, and its preparation condition is: the mass ratio of polylactic acid-glycolic acid copolymer and carbamazepine is 1:5 , The molar ratio of lactic acid to glycolic acid in the polylactic acid-glycolic acid copolymer is 50:50, the pressure is 30MPa, the temperature is 40°C, the time in the kettle is 1h, and the carbon dioxide escape time is 1h.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a method for preparing a carbamazepine PLGA (poly lactic-co-glycolic acid) copolymer micro capsule through a supercritical fluid injection method. The method comprises the following steps: firstly dissolving carbamazepine into supercritical carbon dioxide; secondly, feeding the supercritical carbon dioxide which is dissolved with the carbamazepine into a substrate to be maintained for 1 to 5 hours through the plasticization and swelling of PLGA copolymer, and enabling the carbamazepine to be balanced in distribution between the supercritical carbon dioxide and the PLGA copolymer; finally escaping the carbon dioxide, reserving the carbamazepine in the PLGA copolymer substrate, and preparing the carbamazepine PLGA copolymer micro capsule. The carbamazepine PLGA copolymer micro capsule which is prepared through the method is high in solubility and dissolution rate.

Description

technical field [0001] The invention relates to a method for preparing carbamazepine polylactic acid-glycolic acid copolymer microcapsules. Background technique [0002] The dissolution rate and dissolution rate of crystalline drugs in aqueous solution are generally relatively low, and it is usually necessary to disperse the drug in a polymer carrier to improve the dissolution rate. The biopharmaceutical classification system divides drugs into four types according to their dissolution rate and permeability in the gastrointestinal tract, among which type II drugs have low dissolution rate and good permeability, so increasing the dissolution rate of type II drugs is the research goal important direction. When the dose of type II drugs is not high, the connection between in vitro and in vivo experiments can predict the dissolution rate, so the dissolution test can provide useful information for the bioavailability of the drug. [0003] There are many difficult problems in th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/50A61K47/34A61K31/55
Inventor 王志祥党蓓蕾林文黄德春乐龙
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products